ChemoCentryx Raises Series D

ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has raised $29.84 million in Series D funding, according to a regulatory filing. Glaxo Group Ltd. was joined by return backers like Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors. www.chemocentryx.com